KOPRANNSEKopran Limited· PharmaceuticalsMediumNeutral
Announced Thu, 1 Jan · 16:34 IST

Kopran Limited has informed the Exchange about Credit Rating

Credit & Debt View source PDF

KOPRAN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

CRISIL has reaffirmed the credit ratings on Kopran Limited's bank loan facilities of Rs. 69.31 crore and its subsidiary Kopran Research Laboratories Limited's bank loan facilities of Rs. 124.75 crore. The long-term rating stands at CRISIL BBB+ and short-term rating at CRISIL A2, both placed on 'rating watch with developing implications' until March 31, 2026. The 'developing' tag means CRISIL is monitoring events that could lead to either an upgrade or downgrade in the future. The total rated exposure across the company and its subsidiary is approximately Rs. 194.06 crore.

Likely market impact

The reaffirmation of BBB+ (investment grade) rating signals that Kopran's credit quality remains stable, but the 'watch with developing implications' creates some uncertainty, meaning investors should watch for further updates. This is a mixed/neutral signal for shareholders — no immediate negative impact, but pending events could shift the rating either way.